Trial Profile
Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2019
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Atenolol (Primary) ; Atorvastatin (Primary) ; Bendroflumethiazide; Perindopril
- Indications Cardiovascular disorders; Coronary artery disease; Essential hypertension; Myocardial infarction
- Focus Therapeutic Use
- Acronyms ASCOT; ASCOT-10; ASCOT-BPLA; ASCOT-LLA; CAFE; CAFE-DIABETES; CARAT; EVIREST
- 26 Aug 2018 16-Year follow-up results published in The Lancet.
- 30 Aug 2017 Results of post hoc analysis of ASCOT lipid lowering arm evaluating safety and efficacy among patients treated with amlodipine, perindopril atorvastatin or placebo presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 02 Sep 2015 Substudy results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology